Is ketamine addictive? A straight answer
A direct answer to a question we hear often, in nine steps: what the risk is, what changes it, and what the evidence shows.
Every step has both. The science view adds the strength of evidence and references.
The 3D view is not available on this device.
Outside · the setting · drag to rotateSupervised
Step 1 of 9
A fair question.
Can ketamine or esketamine be addictive? Yes, they can be misused. Both are controlled substances, in the same federal category as testosterone and below opioid pain medicines and stimulants.
Schedule IIOpioid pain medicines such as oxycodone. Stimulants such as Adderall and Ritalin.Schedule IIIKetamine and esketamine. Also testosterone, and Tylenol with codeine.Schedule IVAnxiety medicines such as Xanax and Ativan. Sleep medicines such as Ambien.So the useful question is a narrower one: what is the risk when it is given as a medical treatment, in a clinic, at these doses?
The picture above the model is a treatment visit: a patient in a recliner, a clinician, a monitor, and one dose.
Scheduling and abuse liability
Regulatory factKetamine and esketamine are Schedule III under the Controlled Substances Act. Most opioid analgesics and prescription stimulants are Schedule II; benzodiazepines and zolpidem are Schedule IV. Schedules reflect legal judgments about abuse potential and medical use and are not a precise ranking of risk. The esketamine label carries a boxed warning for abuse and misuse.
Step 2 of 9
How addiction develops.
Addiction grows from a pattern: a drug taken often, in rising amounts, by the person’s own hand, for its effect. Each use sends a surge through the brain’s reward circuit.
With repetition, the surges train the circuit to want more, and the part of the brain that says “stop” loses its grip.
In the model, the reward hub is being hit by fast, repeated surges, and the blue self-control signal is faint.
The neurobiology of addiction
Well establishedSimplified modelAddiction involves repeated drug-induced activation of mesolimbic reward pathways, followed by neuroadaptations that increase incentive salience, produce negative emotional states in withdrawal, and weaken prefrontal executive control. Speed of onset, dose, frequency and self-administration all raise risk.
Step 3 of 9
The test is what happens to a life.
There is a simple way to tell misuse of a drug from treatment with a medicine: look at how the person is functioning.
When a drug is misused, life gets smaller. Work, school, relationships, self-care and the things a person used to enjoy all decline. The drug takes on a life of its own. It starts to drive decisions, and getting it takes up more and more time.
A psychiatric medicine is meant to do the opposite. When ketamine or esketamine is used properly, depression lifts and those same parts of life improve.
Part of lifeTreatment that is workingMisuseWork or schoolImprovesDeclinesRelationshipsImproveStrain or breakSelf-careImprovesDeclinesEnjoymentReturnsNarrows to the drugTime and decisionsGo back to the person’s own lifeGo to getting and using the drugThis is what we watch at every visit: whether life is getting bigger.
In the model, the reward signal is steady and the self-control signal is strong, the pattern seen when treatment is working.
Functional impairment defines a substance use disorder
Well establishedThe DSM-5 criteria for a substance use disorder center on impaired control, social and occupational impairment, risky use, and a great deal of time spent obtaining, using or recovering from the substance. Treatment of depression aims the other way: remission of symptoms and recovery of function across work, relationships and daily life.
Step 4 of 9
Four things raise or lower the risk.
Addiction shows up as a pattern: losing control over use, needing more for the same effect (tolerance), and feeling unwell without it (dependence). Four factors make that pattern more or less likely, wherever the medicine is taken.
FactorLower riskHigher riskDoseLow, measured, set by a clinicianHigh, or rising over timeFrequencyDays or weeks apartDaily or moreMonitoringSomeone checks in at each doseNo one following alongSupplyLimited, trackedLarge amounts on handAt our clinic, every dose is given and monitored on site, which keeps all four low by design.
In the model, the reward signal now arrives as a small, slow pulse, and the self-control signal is steady.
Why supervised dosing differs
Well establishedRisk is lower, not zeroEsketamine is available only through a Risk Evaluation and Mitigation Strategy that requires administration and at least two hours of monitoring in a certified healthcare setting; it is never dispensed to patients. Antidepressant doses of ketamine are subanesthetic and far below typical recreational exposure, and dosing is intermittent. An expert consensus statement concluded that misuse potential in clinical use has not been excluded.
Step 5 of 9
What the record shows.
In studies following patients on esketamine for a year or more, researchers looked for drug-seeking, requests for extra doses, and withdrawal. They did not find a pattern of addiction.
In nearly five years of U.S. use, covering about 1.5 million treatment sessions, 210 reports of abuse or misuse of any kind were recorded. That is uncommon. It is not zero, which is why monitoring continues for every patient.
Clinic ketamine by infusion or injection has been studied less than esketamine, so the same care applies.
The model shows the three parts of the circuit under supervised dosing.
Long-term and postmarketing safety data
Trials and surveillanceReports are voluntary and may undercountIn the one-year SUSTAIN-2 study there were no reports of drug seeking, overdose or abuse and no requests to exceed protocol dosing. A 58-month U.S. postmarketing analysis of 1,486,213 sessions identified 210 cases of all-cause abuse or misuse. A WHO pharmacovigilance analysis found disproportionate substance-related reports for ketamine but not for esketamine. Racemic ketamine in clinical use lacks a comparable registry.
Step 6 of 9
Outside a clinic, the risk is higher.
Street and party use involves much larger doses, taken often. That pattern can lead to addiction, and to lasting bladder damage.
Ketamine mailed for use at home sits in between. It reaches people who live far from a clinic, and that is a real benefit. It also means the dose is not monitored in person, so the risk factors need more attention. The FDA has issued a caution about this. Many people use it responsibly, and it works best with a clinician who knows you and checks in regularly.
In the picture, the clinician and the monitor are gone and the doses have multiplied. In the model, the surges return.
Nonmedical and unsupervised use
Well establishedAt-home data are limitedFrequent high-dose nonmedical ketamine use is associated with dependence, cognitive impairment and ulcerative cystitis. In October 2023 the FDA warned that compounded ketamine used at home without monitoring may place patients at risk of serious adverse events, misuse and abuse, and noted that such products are not FDA approved.
Step 7 of 9
If addiction is part of your story.
A past addiction does not rule this treatment out. Tell us about it. We plan around it, and we watch more closely.
If someone is in the middle of a serious addiction, that needs its own treatment first or alongside: medical withdrawal care, a recovery program, and for opioids, medicines such as buprenorphine. Ketamine does not replace any of that.
Some people drink or use cannabis to push down depression or anxiety. When the depression is treated well, that pull often eases. Not always, so we keep asking, and so should you.
In the model, both signals are supported together: the reward circuit settles and self-control strengthens.
Depression with a substance use disorder
Limited direct evidenceClinical judgment requiredThe pivotal esketamine trials excluded patients with a recent moderate or severe substance use disorder, so evidence in this group is observational. In one real-world cohort, 26 patients with TRD and a comorbid SUD improved on esketamine with no cases of misuse. Guidelines favor integrated treatment of co-occurring depression and substance use; antidepressant treatment has a modest effect on mood and a smaller effect on substance use. For opioid use disorder, medication treatment is the standard of care and withdrawal management alone carries a high relapse risk.
Step 8 of 9
Could ketamine help treat addiction?
Possibly. In small studies, ketamine given alongside therapy helped some people with alcohol, cocaine or opioid addiction cut down or stay abstinent for longer.
This research is early. It is not a standard treatment, and where it has worked it was one part of a full recovery program.
Move the slider under the picture, or press Play, to see how structure changes the picture.
The model shows the supervised pattern with the self-control signal supported.
Ketamine for substance use disorders
Early clinical evidenceNot standard of careA 2025 systematic review of 14 studies and 551 participants found short-term reductions in craving and improved abstinence in alcohol, cocaine and opioid use disorders, often with ketamine paired with psychotherapy, and concluded that the evidence is limited by small samples and few randomized trials. Effects on relapse prevention have been inconsistent.
Step 9 of 9
The takeaway: watch the life.
Misuse makes a life smaller. Treatment that is working makes it bigger.
If work, relationships, self-care and enjoyment are improving, the medicine is doing its job. If they start to slip, or the medicine starts to take priority over the life around it, we change the plan.
That is the question we ask at every visit, and one you and your family can ask too.
The model ends where treatment aims: a steady reward signal and strong self-control.
Function is the measure
Well establishedImpaired functioning and loss of control are core features of a substance use disorder. In depression treatment, recovery of function across work, relationships and daily life is a central goal alongside symptom remission, and it is monitored throughout care.
What this picture simplifies
- The slider treats supervision as one dial. In life, dose, frequency, setting and supply each play a separate part.
- Prescribed at-home ketamine is not the same as street use. It sits between the two ends shown here.
- Addiction involves much more than one circuit, including genetics, stress and environment.
- Low risk across many patients does not mean no risk for one person. That is what monitoring is for.
This guide is educational and does not replace a medical evaluation. The scene is an illustration and does not depict a patient.
The takeaway
- Ketamine and esketamine can be misused. In a supervised clinic the risk is low, and it is not zero.
- Dose, frequency, monitoring and supply all change the risk.
- The test is how you are functioning. Treatment that is working makes life bigger.
What you can do next
- Tell us about any history of addiction. It does not rule treatment out.
- Bring your questions about this to your evaluation.
- Ask your family to watch what we watch: whether your life is getting bigger.
Questions about your own history?
Bring them to the evaluation. An honest history helps us plan safe treatment. A first consultation is an evaluation, not a commitment to any treatment.